A recent preliminary review conducted by the U.S. Food and Drug Administration (FDA) has found no evidence linking popular drugs used to treat diabetes and obesity with an increased risk of suicidal thoughts or actions. While the review is encouraging, the FDA acknowledges that there may still be a small risk, and they will continue to investigate the matter.
The FDA reviewed the safety profiles of over a dozen drugs, including Ozempic, Wegovy, and Mounjaro. They based their findings on reports from patients who have been using these medications. The agency emphasized the importance of patients reporting any concerns or side effects to their healthcare providers.
